Scientific Program

Preliminary Program


Wednesday afternoon 5 September
Systemic connective tissue diseases with a focus on systemic sclerosis
Challenges of systemic sclerosis in clinical practice
Roger Hesselstrand
Capillaroscopy in diagnosis and follow-up of systemic sclerosis
To be announced
Case 1 – Denmark
Case 2 – Sweden
Case 3 – Norway
Case 4 – Finland


Thursday  6 September
9.30–11.45 Session 1
Update on synthetic and biologic therapies
Methotrexate - mechanisms of action in arthritis
John Isaacs
Glucocorticoids - mechanisms of action in arthritis and joint pain
• Jan Tuckermann
10.30–10.45 Break
Clinical experience on switching to biosimilar
• Tore Kvien

The clinical significance of drug level and anti-drug antibody testing in patients using biologic therapies
Sakari Jokiranta
11.45-12.30 Lunch 
12.30–14.00 Parallel session 2
Burden of Rheumatoid Arthritis
Cardiovascular disease and rheumatoid arthritis
Anne Grete Semb
Malignancies and rheumatoid arthritis
• Johan Askling

Costs and rheumatoid arthritis
Vappu Rantalaiho
Parallel session 3
Lymphocyte responses in autoimmune diseases
Abnormal vaccination responses in SS
Marie Wahren-Herlenius
Somatic mutations in cytotoxic T lymphocytes in RA
Satu Mustjoki
Abnormal STAT activity in lymphoid cells in autoimmune diseases
Pia Isomäki
14.00–14.30 Coffee break 
14.30–15.30 Parallel session 4
Autoinflammatory syndromes
Autoinflammatory syndromes in the past and in the future
Daniel Kastner
Novel autoinflammatory syndromes
Kari Eklund
Parallel session 5
Pain in arthritis patients
Neuropathic pain and pain sensitisation in arthritis
Lars Arendt-Nielsen
Pain catastrophizing in arthritis patients
Hilde Hammer
15.30–16.30 SCR General Assembly 
17.30–18.30 Opening ceremony including opening lecture
What is pre-clinical RA?
Solbritt Rantapää-Dahlqvist


Friday 7  September
8.00–9.00 Satellite symposium
9.10–10.40 Parallel session 6
Epidemiology of SLE
Pia Elfving
Pathogenesis of SLE
Christopher Sjöwall
Modern management of SLE
Søren Jacobsen 
Parallel session 7
Genetics and gene expression
Epigenetics: DNA methylation and histone acetylation
Steffen Gay
Pharmacogenetics in RA
To be announced
Elevated abstracts
10.40–11.00 Coffee break 
11.00–12.30 Parallel session 8
Spondylarthritis and seronegative arthritis
Impact of axial-SPA
Desiree van der Hejde
Burden of psoriatic arthritis
• Thorvardur Jon Love

Long-term outcomes of seronegative arthritis
Elena Nikiphorou
Parallel session 9
Innate immunity in arthritis
Macrophage phenotypes in arthritis
• Irina Udalova

Complement system as a therapeutic target in rheumatic diseases
• To be announced

Reactive oxygen species in arthritis
Rikard Holmdahl
12.30–13.30 Lunch 
13.30–15.00 Parallel session 10
Hyperuricemia and gout
Epidemiology of hyperuricemia
Markku Kauppi
Modern imaging in gout – the role of dual energy CT and ultrasonography
• Lene Terslev

Modern treatment of gout
Till Uhlig
Parallel session 11
Signal transduction pathways in arthritis
TRP channels in arthritis
Katsuhiko Muraki
TGF-beta in arthritis
Peter van der Kraan
Regulation of the activity of JAK-STAT signalling pathways
Olli Silvennoinen
15.00–15.30 Coffee break 
15.30–17.00 Parallel session 12
Osteoarthritis - an inflammatory disease
Ali Mobasheri
Innate immunity in osteoarthritis, focus on TLRs and NLRs
Michiaki Takagi
Novel treatment options for OA
Eeva Moilanen
Parallel session 13
Myositis and myopathy
Differential diagnostics of myopathies in 2018
Manu Jokela
Myositis in 2018. New tools for diagnosis and therapy
• Ingrid Lundberg

Elevated abstracts
17.15–18.15 Satellite symposium 


Saturday 8  September
8.00–9.00 Satellite symposium
9.15–10.30 Parallel session 14
New imaging techniques in rheumatology
• Ellen Hauge

Optical imaging
Mads Ammitzbøll-Danielsen
Whole-body MRI
Simon Krabbe
Parallel session 15
Anti-citrulline and anti-carbamylated protein antibodies in rheumatoid arthritis
The pathogenetic significance of anti-citrulline antibodies
Anca Catrina
Anti-carbamylated protein antibodies
Leendert A Trouw
Elevated abstracts
10.30–11.00 Coffee break 
11.00–12.30 Parallel session 16
New therapies in inflammatory arthritides
Update on new and upcoming therapies in RA
Jon Lampa
Clinical registries in the Nordic Countries – real world data
Bente Glintborg
Can biologic drugs be tapered?
Espen Haavardsholm
Parallel session 17
Novel contributors in the etiopathogenesis of arthritis
Gut microbiota and arthritis
Francesco Ciccia
Obesity and adipokines in osteoarthritis
Katriina Vuolteenaho
Resolution inducing lipid mediators in arthritis
Per-Johan Jakobsson

12.30–13.00 Closing session
Rheumatology in 2040
• Lars Kristensen

13.00–14.00 Lunch